HLS — HLS Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$137.60m
- CA$189.89m
- $55.50m
Annual income statement for HLS Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | Interim Report | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 60 | 61.5 | 63.1 | 56.6 | 55.5 |
| Cost of Revenue | |||||
| Gross Profit | 56 | 56.5 | 55.5 | 47.6 | 45.4 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 71.8 | 85.2 | 90.9 | 72.2 | 68.4 |
| Operating Profit | -11.8 | -23.7 | -27.8 | -15.6 | -12.9 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11.8 | -23.7 | -27.8 | -15.6 | -12.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.1 | -23.6 | -27.5 | -19.7 | -12.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.1 | -23.6 | -27.5 | -19.7 | -12.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.1 | -23.6 | -27.5 | -19.7 | -12.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.404 | -0.624 | -0.728 | -0.686 | -0.397 |
| Dividends per Share |